Comparison of select COVID-19 vaccines worldwide 2022, by efficacy against Delta

Published by
Matej Mikulic,
Apr 11, 2022
As of February 2022, the latest COVID-19 vaccine by Sanofi/GlaxoSmithKline showed a 77 percent efficacy against the Delta variant of the coronavirus. This statistic illustrates the comparison of select COVID-19 vaccines worldwide, by their efficacy against the Delta variant.

Comparison of select COVID-19 vaccines worldwide as of 2022, by efficacy against Delta variant

Loading statistic...

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

February 2022

Region

Worldwide

Survey time period

as of February 2022

Supplementary notes

* Early data, sequencing still in progress.

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Pfizer "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Pfizer

Global positioning

7

Key company data

6

Business distribution

4

Competitors

5

COVID-19

6

Further Content: You might find this interesting as well

Topics

PfizerGlobal pharmaceutical industryPharmaceutical industry in the U.S.NovartisMerck & Co.
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Learn more about how Statista can support your business.
Menu